Association	O
of	O
β-	O
blocker	O
therapy	O
with	O
long	O
-	O
term	O
clinical	B:C4055223
outcomes	I:C4055223
in	O
patients	O
with	O
coronary	O
chronic	I:C1955779
total	I:C1955779
occlusion	I:C1955779
.	O

Association	O
of	O
β-	O
blocker	O
therapy	O
with	O
long	O
-	O
term	O
clinical	O
outcomes	I:C4055223
in	O
patients	O
with	O
coronary	B:C1955779
chronic	I:C1955779
total	I:C1955779
occlusion	I:C1955779
.	O

There	O
are	O
limited	O
data	O
regarding	O
the	O
efficacy	O
of	O
β-	B:C0001645
blockers	I:C0001645
for	O
secondary	O
prevention	I:C0679699
in	O
patients	O
with	O
coronary	O
chronic	I:C1955779
total	I:C1955779
occlusion	I:C1955779
(	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
)	O
.	O

There	O
are	O
limited	O
data	O
regarding	O
the	O
efficacy	O
of	O
β-	O
blockers	I:C0001645
for	O
secondary	B:C0679699
prevention	I:C0679699
in	O
patients	O
with	O
coronary	O
chronic	I:C1955779
total	I:C1955779
occlusion	I:C1955779
(	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
)	O
.	O

There	O
are	O
limited	O
data	O
regarding	O
the	O
efficacy	O
of	O
β-	O
blockers	I:C0001645
for	O
secondary	O
prevention	I:C0679699
in	O
patients	O
with	O
coronary	B:C1955779
chronic	I:C1955779
total	I:C1955779
occlusion	I:C1955779
(	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
)	O
.	O

There	O
are	O
limited	O
data	O
regarding	O
the	O
efficacy	O
of	O
β-	O
blockers	I:C0001645
for	O
secondary	O
prevention	I:C0679699
in	O
patients	O
with	O
coronary	O
chronic	I:C1955779
total	I:C1955779
occlusion	I:C1955779
(	O
chronic	B:C1955779
total	I:C1955779
occlusion	I:C1955779
)	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
association	O
of	O
β-	O
blocker	O
therapy	O
with	O
long	O
-	O
term	O
clinical	B:C4055223
outcomes	I:C4055223
in	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
patients	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
association	O
of	O
β-	O
blocker	O
therapy	O
with	O
long	O
-	O
term	O
clinical	O
outcomes	I:C4055223
in	O
chronic	B:C1955779
total	I:C1955779
occlusion	I:C1955779
patients	O
.	O

From	O
March	O
2003	O
to	O
February	O
2012	O
,	O
a	O
total	O
of	O
2024	O
chronic	B:C1955779
total	I:C1955779
occlusion	I:C1955779
patients	O
treated	O
with	O
either	O
medical	O
therapy	I:C0418981
alone	O
or	O
revascularization	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

From	O
March	O
2003	O
to	O
February	O
2012	O
,	O
a	O
total	O
of	O
2024	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
patients	O
treated	O
with	O
either	O
medical	B:C0418981
therapy	I:C0418981
alone	O
or	O
revascularization	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

From	O
March	O
2003	O
to	O
February	O
2012	O
,	O
a	O
total	O
of	O
2024	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
patients	O
treated	O
with	O
either	O
medical	O
therapy	I:C0418981
alone	O
or	O
revascularization	B:C0581603
were	O
enrolled	O
in	O
the	O
study	O
.	O

From	O
March	O
2003	O
to	O
February	O
2012	O
,	O
a	O
total	O
of	O
2024	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
patients	O
treated	O
with	O
either	O
medical	O
therapy	I:C0418981
alone	O
or	O
revascularization	O
were	O
enrolled	O
in	O
the	O
study	B:C2603343
.	O

We	O
assessed	O
1596	O
patients	O
with	O
stable	O
ischemic	B:C0151744
heart	I:C0151744
disease	I:C0151744
and	O
divided	O
them	O
into	O
the	O
β	O
-	I:C0001645
blocker	I:C0001645
group	O
(	O
n	O
=	O
932	O
)	O
and	O
the	O
no	O
-	O
β-	O
blocker	I:C0001645
group	O
(	O
n	O
=	O
664	O
)	O
.	O

We	O
assessed	O
1596	O
patients	O
with	O
stable	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
and	O
divided	O
them	O
into	O
the	O
β	B:C0001645
-	I:C0001645
blocker	I:C0001645
group	O
(	O
n	O
=	O
932	O
)	O
and	O
the	O
no	O
-	O
β-	O
blocker	I:C0001645
group	O
(	O
n	O
=	O
664	O
)	O
.	O

We	O
assessed	O
1596	O
patients	O
with	O
stable	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
and	O
divided	O
them	O
into	O
the	O
β	O
-	I:C0001645
blocker	I:C0001645
group	O
(	O
n	O
=	O
932	O
)	O
and	O
the	O
no	O
-	O
β-	B:C0001645
blocker	I:C0001645
group	O
(	O
n	O
=	O
664	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
all	B:C0007465
-	I:C0007465
cause	I:C0007465
death	I:C0007465
.	O

The	O
median	B:C2939193
follow	O
-	I:C1522577
up	I:C1522577
duration	O
was	O
3.9	O
(	O
interquartile	O
range	O
:	O
2.0	O
-	O
6.2	O
)	O
years	O
.	O

The	O
median	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
duration	O
was	O
3.9	O
(	O
interquartile	O
range	O
:	O
2.0	O
-	O
6.2	O
)	O
years	O
.	O

All	B:C0007465
-	I:C0007465
cause	I:C0007465
death	I:C0007465
occurred	O
in	O
11.6	O
%	O
patients	O
in	O
the	O
β	O
-	I:C0001645
blocker	I:C0001645
group	O
and	O
13.6	O
%	O
patients	O
in	O
the	O
no	O
-	O
β-	O
blocker	I:C0001645
group	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
:	O
0.81	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0.61	O
-1.08	O
;	O
P	O
=	O
0.15	O
)	O
.	O

All	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
occurred	O
in	O
11.6	O
%	O
patients	O
in	O
the	O
β	B:C0001645
-	I:C0001645
blocker	I:C0001645
group	O
and	O
13.6	O
%	O
patients	O
in	O
the	O
no	O
-	O
β-	O
blocker	I:C0001645
group	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
:	O
0.81	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0.61	O
-1.08	O
;	O
P	O
=	O
0.15	O
)	O
.	O

All	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
occurred	O
in	O
11.6	O
%	O
patients	O
in	O
the	O
β	O
-	I:C0001645
blocker	I:C0001645
group	O
and	O
13.6	O
%	O
patients	O
in	O
the	O
no	O
-	O
β-	B:C0001645
blocker	I:C0001645
group	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
:	O
0.81	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0.61	O
-1.08	O
;	O
P	O
=	O
0.15	O
)	O
.	O

In	O
the	O
propensity	O
score	O
-	O
matched	B:C1257890
population	I:C1257890
(	O
570	O
pairs	O
)	O
,	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
occurred	O
in	O
12.3	O
%	O
patients	O
in	O
the	O
β	O
-	I:C0001645
blocker	I:C0001645
group	O
and	O
12.8	O
%	O
patients	O
in	O
the	O
no	O
-	O
β-	O
blocker	I:C0001645
group	O
(	O
HR	O
:	O
0.93	O
,	O
95	O
%	O
CI	O
:	O
0.67	O
-	O
1.29	O
;	O
P	O
=	O
0.66	O
)	O
.	O

In	O
the	O
propensity	O
score	O
-	O
matched	O
population	I:C1257890
(	O
570	O
pairs	O
)	O
,	O
all	B:C0007465
-	I:C0007465
cause	I:C0007465
death	I:C0007465
occurred	O
in	O
12.3	O
%	O
patients	O
in	O
the	O
β	O
-	I:C0001645
blocker	I:C0001645
group	O
and	O
12.8	O
%	O
patients	O
in	O
the	O
no	O
-	O
β-	O
blocker	I:C0001645
group	O
(	O
HR	O
:	O
0.93	O
,	O
95	O
%	O
CI	O
:	O
0.67	O
-	O
1.29	O
;	O
P	O
=	O
0.66	O
)	O
.	O

In	O
the	O
propensity	O
score	O
-	O
matched	O
population	I:C1257890
(	O
570	O
pairs	O
)	O
,	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
occurred	O
in	O
12.3	O
%	O
patients	O
in	O
the	O
β	B:C0001645
-	I:C0001645
blocker	I:C0001645
group	O
and	O
12.8	O
%	O
patients	O
in	O
the	O
no	O
-	O
β-	O
blocker	I:C0001645
group	O
(	O
HR	O
:	O
0.93	O
,	O
95	O
%	O
CI	O
:	O
0.67	O
-	O
1.29	O
;	O
P	O
=	O
0.66	O
)	O
.	O

In	O
the	O
propensity	O
score	O
-	O
matched	O
population	I:C1257890
(	O
570	O
pairs	O
)	O
,	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
occurred	O
in	O
12.3	O
%	O
patients	O
in	O
the	O
β	O
-	I:C0001645
blocker	I:C0001645
group	O
and	O
12.8	O
%	O
patients	O
in	O
the	O
no	O
-	O
β-	B:C0001645
blocker	I:C0001645
group	O
(	O
HR	O
:	O
0.93	O
,	O
95	O
%	O
CI	O
:	O
0.67	O
-	O
1.29	O
;	O
P	O
=	O
0.66	O
)	O
.	O

In	O
subgroup	O
analysis	B:C0936012
,	O
β-	O
blocker	O
therapy	O
was	O
associated	O
with	O
better	O
outcome	O
,	O
in	O
terms	O
of	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
,	O
in	O
patients	O
with	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
of	O
the	O
left	O
anterior	I:C0226032
descending	I:C0226032
coronary	I:C0226032
artery	I:C0226032
and	O
Synergy	O
Between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
(	O
SYNTAX	O
)	O
score	O
≥	O
23	O
(	O
P	O
for	O
interaction	O
=	O
0.01	O
and	O
0.02	O
,	O
respectively	O
)	O
.	O

In	O
subgroup	O
analysis	O
,	O
β-	O
blocker	O
therapy	O
was	O
associated	O
with	O
better	O
outcome	O
,	O
in	O
terms	O
of	O
all	B:C0007465
-	I:C0007465
cause	I:C0007465
death	I:C0007465
,	O
in	O
patients	O
with	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
of	O
the	O
left	O
anterior	I:C0226032
descending	I:C0226032
coronary	I:C0226032
artery	I:C0226032
and	O
Synergy	O
Between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
(	O
SYNTAX	O
)	O
score	O
≥	O
23	O
(	O
P	O
for	O
interaction	O
=	O
0.01	O
and	O
0.02	O
,	O
respectively	O
)	O
.	O

In	O
subgroup	O
analysis	O
,	O
β-	O
blocker	O
therapy	O
was	O
associated	O
with	O
better	O
outcome	O
,	O
in	O
terms	O
of	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
,	O
in	O
patients	O
with	O
chronic	B:C1955779
total	I:C1955779
occlusion	I:C1955779
of	O
the	O
left	O
anterior	I:C0226032
descending	I:C0226032
coronary	I:C0226032
artery	I:C0226032
and	O
Synergy	O
Between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
(	O
SYNTAX	O
)	O
score	O
≥	O
23	O
(	O
P	O
for	O
interaction	O
=	O
0.01	O
and	O
0.02	O
,	O
respectively	O
)	O
.	O

In	O
subgroup	O
analysis	O
,	O
β-	O
blocker	O
therapy	O
was	O
associated	O
with	O
better	O
outcome	O
,	O
in	O
terms	O
of	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
,	O
in	O
patients	O
with	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
of	O
the	O
left	B:C0226032
anterior	I:C0226032
descending	I:C0226032
coronary	I:C0226032
artery	I:C0226032
and	O
Synergy	O
Between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
(	O
SYNTAX	O
)	O
score	O
≥	O
23	O
(	O
P	O
for	O
interaction	O
=	O
0.01	O
and	O
0.02	O
,	O
respectively	O
)	O
.	O

In	O
subgroup	O
analysis	O
,	O
β-	O
blocker	O
therapy	O
was	O
associated	O
with	O
better	O
outcome	O
,	O
in	O
terms	O
of	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
,	O
in	O
patients	O
with	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
of	O
the	O
left	O
anterior	I:C0226032
descending	I:C0226032
coronary	I:C0226032
artery	I:C0226032
and	O
Synergy	O
Between	O
PCI	B:C1532338
with	O
Taxus	O
and	O
Cardiac	O
Surgery	I:C0018821
(	O
SYNTAX	O
)	O
score	O
≥	O
23	O
(	O
P	O
for	O
interaction	O
=	O
0.01	O
and	O
0.02	O
,	O
respectively	O
)	O
.	O

In	O
subgroup	O
analysis	O
,	O
β-	O
blocker	O
therapy	O
was	O
associated	O
with	O
better	O
outcome	O
,	O
in	O
terms	O
of	O
all	O
-	I:C0007465
cause	I:C0007465
death	I:C0007465
,	O
in	O
patients	O
with	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
of	O
the	O
left	O
anterior	I:C0226032
descending	I:C0226032
coronary	I:C0226032
artery	I:C0226032
and	O
Synergy	O
Between	O
PCI	O
with	O
Taxus	O
and	O
Cardiac	B:C0018821
Surgery	I:C0018821
(	O
SYNTAX	O
)	O
score	O
≥	O
23	O
(	O
P	O
for	O
interaction	O
=	O
0.01	O
and	O
0.02	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
β-	O
blocker	O
therapy	O
was	O
not	O
associated	O
with	O
favorable	O
long	O
-	O
term	O
clinical	B:C4055223
outcomes	I:C4055223
in	O
stable	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
patients	O
,	O
regardless	O
of	O
treatment	O
strategy	O
.	O

In	O
conclusion	O
,	O
β-	O
blocker	O
therapy	O
was	O
not	O
associated	O
with	O
favorable	O
long	O
-	O
term	O
clinical	O
outcomes	I:C4055223
in	O
stable	O
chronic	B:C1955779
total	I:C1955779
occlusion	I:C1955779
patients	O
,	O
regardless	O
of	O
treatment	O
strategy	O
.	O

In	O
conclusion	O
,	O
β-	O
blocker	O
therapy	O
was	O
not	O
associated	O
with	O
favorable	O
long	O
-	O
term	O
clinical	O
outcomes	I:C4055223
in	O
stable	O
chronic	O
total	I:C1955779
occlusion	I:C1955779
patients	O
,	O
regardless	O
of	O
treatment	B:C0087111
strategy	O
.	O

However	O
,	O
β-	O
blocker	O
therapy	O
might	O
be	O
beneficial	O
in	O
a	O
highly	O
selective	O
group	O
of	O
chronic	B:C1955779
total	I:C1955779
occlusion	I:C1955779
patients	O
with	O
a	O
high	O
ischemic	O
burden	O
.	O

